One year ago today, the FDA buckled to pressure from a savvy astroturf campaign and approved the female libido drug flibanserin (brand name: Addyi). In response, we launched the “Pass on the Pink Pill – Or Pass Out” campaign to warn women of the marginal benefits and serious side effects of the “pink pill”—complications like dangerously low blood pressure, dizziness, and even sudden loss of consciousness!
Today we reflect back on the broken promises, missing safety studies, and more in our report card, “Addyi One Year Later: What’s the Score?”
It won’t surprise you that the drug gets bad grades for safety and effectiveness, or that drug maker Valeant—the pharmaceutical giant known for price gouging and shady business practices—hasn’t reported the results of any of the post-market safety studies it was told to conduct, even as it charges women $800 for a month of pills.
But we are thrilled with one of Addyi’s grades so far: we were happy to give it an F for “demand.” At its sales peak in March, only 1,500 prescriptions were written.
So take a look and help us spread the word! If you want to learn more about how this bogus drug got on the market or the top 10 things women should know when considering this drug, check out our website.
And remember, you can count on us to provide you with trustworthy women’s health advocacy, free from the influence of drug and device makers. We hope you will continue to support the work of NWHN by becoming a member and making a donation today!